Amy Pauli
Overview
Amy advises the country’s largest companies through high-stakes litigation matters. She litigates breach of contract, breach of fiduciary duty, false advertising, unfair competition, consumer protection, and antitrust disputes in federal courts nationwide. Her clients include universities, retailers, food and beverage manufacturers and distributors, consumer products manufacturers, and aerospace and health care companies. She also represents corporate victims of price-fixing and anticompetitive conduct in affirmative recovery litigation.
Career & Education
- U.S. Court of Appeals for the Tenth Circuit
Judicial Clerk, Honorable Gregory A. Phillips, 2017–2018
- U.S. Court of Appeals for the Tenth Circuit
- University of Utah, J.D., highest honors, Order of the Coif, executive social justice editor, Utah Law Review, 2017
- University of Wyoming, B.A., 2014
- Colorado
- Wyoming
- U.S. District Court for the District of Colorado
- U.S. Court of Appeals for the Seventh Circuit
- U.S. Court of Appeals for the Ninth Circuit
- U.S. Court of Appeals for the Tenth Circuit
Professional Activities and Memberships
- Member, Colorado Women’s Bar Association
- Board of Directors, Denver Urban Debate League
- Participant, LCLD 2021 Pathfinder Program
- Participant, Impact Denver Spring 2021 Program
Amy's Insights
Client Alert | 5 min read | 02.20.26
Trump Administration Pursues MFN Pricing for Prescription Drugs
By the end of 2025, 16 drug manufacturers had voluntarily negotiated and executed agreements to adopt Most Favored Nation (MFN) pricing for certain high-cost drugs. The Trump Administration highlighted the agreements in its “Great Healthcare Plan,” published on January 15, 2026, and communicated the government’s plans to “codify” such deals as a means of “get[ting] Americans the same low prices that people in other countries pay.” The Administration recently leveraged MFN pricing to establish the TrumpRx website, which helps uninsured or cash-paying consumers find drugs at a discounted price. The website reflects the Administration’s stated commitment to provide more lower-cost drugs directly to consumers. Currently, 40 branded medications are available at reduced prices.
Client Alert | 2 min read | 09.18.25
Client Alert | 2 min read | 06.06.25
Supreme Court Dismisses Cert Petition On Uninjured Class Members As Improvidently Granted
Press Coverage | 05.27.25
Representative Matters
Class Actions
- Secured pleading-stage dismissal of false advertising class action against Fortune 500 food manufacturer.
- Secured dismissal of consumer class action for pet products manufacturer in the U.S. District Court for the Northern District of California. Plaintiff sought $5 million in damages and asserted claims including fraud, breach of warranty, and that the label was misleading under consumer protection statutes.
- Defending health care companies in Mental Health Parity and Addiction Equity Act class actions.
Health Care Litigation and Appeals:
- Challenged and defended, on behalf of an ERISA plan administrator, a series of district court decisions regarding mental health benefits claims before the Second, Seventh, and Tenth Circuit Courts of Appeals.
- Secured summary judgment for ERISA plan administrator in coverage dispute.
- Secured dismissal of California Unfair Competition Law and unjust enrichment class action against large health plan.
Regulatory Business Disputes
- Represented animal product manufacturer in investigation of regulatory defects in business acquired by client and litigation for breaches of acquisition agreement. Successfully brought federal court litigation alleging more than $7 million in damages, resulting in highly favorable settlement for client.
Food Labeling Counseling
- Advising global beverage brand regarding product launches, advertising and marketing risks, and bottle bill compliance for various product lines including juices, sodas and carbonated beverages, flavored waters, and energy drinks.
Amy's Insights
Client Alert | 5 min read | 02.20.26
Trump Administration Pursues MFN Pricing for Prescription Drugs
By the end of 2025, 16 drug manufacturers had voluntarily negotiated and executed agreements to adopt Most Favored Nation (MFN) pricing for certain high-cost drugs. The Trump Administration highlighted the agreements in its “Great Healthcare Plan,” published on January 15, 2026, and communicated the government’s plans to “codify” such deals as a means of “get[ting] Americans the same low prices that people in other countries pay.” The Administration recently leveraged MFN pricing to establish the TrumpRx website, which helps uninsured or cash-paying consumers find drugs at a discounted price. The website reflects the Administration’s stated commitment to provide more lower-cost drugs directly to consumers. Currently, 40 branded medications are available at reduced prices.
Client Alert | 2 min read | 09.18.25
Client Alert | 2 min read | 06.06.25
Supreme Court Dismisses Cert Petition On Uninjured Class Members As Improvidently Granted
Press Coverage | 05.27.25
Insights
A Lawsuit Over Products Marketed as “100% Recyclable” Has Lessons for Fashion
|08.15.22
The Fashion Law
Practices
Industries
Amy's Insights
Client Alert | 5 min read | 02.20.26
Trump Administration Pursues MFN Pricing for Prescription Drugs
By the end of 2025, 16 drug manufacturers had voluntarily negotiated and executed agreements to adopt Most Favored Nation (MFN) pricing for certain high-cost drugs. The Trump Administration highlighted the agreements in its “Great Healthcare Plan,” published on January 15, 2026, and communicated the government’s plans to “codify” such deals as a means of “get[ting] Americans the same low prices that people in other countries pay.” The Administration recently leveraged MFN pricing to establish the TrumpRx website, which helps uninsured or cash-paying consumers find drugs at a discounted price. The website reflects the Administration’s stated commitment to provide more lower-cost drugs directly to consumers. Currently, 40 branded medications are available at reduced prices.
Client Alert | 2 min read | 09.18.25
Client Alert | 2 min read | 06.06.25
Supreme Court Dismisses Cert Petition On Uninjured Class Members As Improvidently Granted
Press Coverage | 05.27.25
